Stockscreener 앱 받기
18.98
3.66%
0.67
시간 외 거래:
19.03
0.05
+0.26%
전일 마감가:
$18.31
열려 있는:
$18.36
하루 거래량:
1.39M
Relative Volume:
0.28
시가총액:
$14.00B
수익:
$956.00K
순이익/손실:
$-196.68M
주가수익비율:
-11.29
EPS:
-1.6811
순현금흐름:
$-113.02M
1주 성능:
-12.82%
1개월 성능:
-10.51%
6개월 성능:
+327.48%
1년 성능:
+883.42%
1일 변동 폭
$18.11
$19.25
1주일 범위
$18.11
$22.25
52주 변동 폭
$1.89
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SMMT | 18.98 | 14.00B | 956.00K | -196.68M | -113.02M | -1.6811 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(SMMT) Trading Report - Stock Traders Daily
Here's Merck's $3.3 Billion Insurance Against Summit's Advance - Investor's Business Daily
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters
Has Summit Therapeutics Stock Already Peaked? - AOL
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
Is Summit Therapeutics a Millionaire Maker? - AOL
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Why Summit Therapeutics Stock Was a Winner Today - MSN
Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily
SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK
Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com
Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK
Summit Therapeutics Leads The Parade Of Big Gainers - Forbes
Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN
3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool
abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Price Target Cut to $44.00 by Analysts at HC Wainwright - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2024 Earnings Call Transcript - Insider Monkey
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales - Yahoo Finance
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Summit Therapeutics reports Q3 EPS (5c), consensus (7c) - MSN
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight - Yahoo Finance
Summit Therapeutics Advances NSCLC Trials and Strengthens Financials - TipRanks
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 10.4%What's Next? - MarketBeat
Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - BioSpace
China Universal Asset Management Co. Ltd. Purchases 56,879 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Tesla, Xpeng, Summit Therapeutics lead Monday's morning market cap stock movers - Investing.com Australia
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
Summit Therapeutics Inc. (SMMT): An Unstoppable Stock That Could Make You Richer - Insider Monkey
Billionaire Buys Miami Penthouse After His Firm’s 689% Stock Rally - MSN
8 Unstoppable Stocks That Could Make You Richer - Insider Monkey
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings? - MSN
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
| Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
| Zanganeh Mahkam | Chief Executive Officer |
Dec 12 '23 |
Buy |
2.07 |
5,000 |
10,350 |
494,814 |
| Dhingra Ankur | Chief Financial Officer |
Dec 13 '23 |
Buy |
2.17 |
20,400 |
44,254 |
254,958 |
1.45%
1.11%
자본화:
|
볼륨(24시간):